-
Table of Contents
Patents and Formulations History of Methandienone Compresse
Methandienone, also known as Dianabol, is a synthetic anabolic-androgenic steroid that has been used in the field of sports pharmacology for decades. It was first developed in the 1950s by Dr. John Ziegler, a physician for the United States Olympic team, and was initially used to help athletes gain muscle mass and improve performance. Since then, it has become one of the most widely used and studied steroids in the world, with a rich history of patents and formulations that have shaped its use and impact on the sports world.
Early Patents and Formulations
The first patent for methandienone was filed in 1956 by Ciba Pharmaceuticals, the company that originally manufactured the drug. This patent described the chemical structure of methandienone and its potential use as an anabolic steroid. It also outlined the potential benefits of the drug, including increased muscle mass, strength, and endurance.
Shortly after the patent was filed, Ciba Pharmaceuticals released the first formulation of methandienone, which was in the form of an oral tablet. This formulation quickly gained popularity among athletes, particularly bodybuilders, due to its ability to rapidly increase muscle mass and strength. However, this early formulation also had a high risk of side effects, including liver toxicity and estrogenic effects such as gynecomastia.
Evolution of Formulations
Over the years, several different formulations of methandienone have been developed in an effort to improve its efficacy and reduce side effects. In the 1960s, Ciba Pharmaceuticals released a new formulation of methandienone in the form of an injectable solution. This formulation was designed to bypass the liver and reduce the risk of liver toxicity. However, it still had a high risk of estrogenic side effects.
In the 1970s, a new formulation of methandienone was developed by the pharmaceutical company, Akrikhin. This formulation, known as Methandrostenolone, was a modified version of methandienone that had a lower risk of estrogenic side effects. It also had a longer half-life, allowing for less frequent dosing. This formulation gained popularity among athletes and bodybuilders, and it is still widely used today.
Patent Controversy
In the 1980s, a patent dispute arose between Ciba Pharmaceuticals and Akrikhin over the rights to manufacture and sell methandienone. Ciba Pharmaceuticals claimed that Akrikhin’s formulation of Methandrostenolone was too similar to their original patent for methandienone. This dispute led to a legal battle that lasted for several years and resulted in the suspension of methandienone production by both companies.
Eventually, the patent dispute was settled, and both companies were allowed to continue manufacturing and selling their respective formulations of methandienone. However, this controversy shed light on the importance of patents in the pharmaceutical industry and the impact they can have on the availability and use of certain drugs.
Current Formulations and Patents
Today, methandienone is still available in both oral and injectable formulations, with various brand names and manufacturers. However, due to its potential for abuse and side effects, it is classified as a controlled substance in many countries and is only available with a prescription.
In recent years, there have been efforts to develop new formulations of methandienone that have a lower risk of side effects and are less detectable in drug tests. One such formulation is known as methandienone undecanoate, which has a longer half-life and is less likely to be detected in urine tests. However, this formulation is still in the early stages of development and has not yet been approved for use.
Expert Opinion
According to Dr. Michael Scally, a leading expert in sports pharmacology, the history of patents and formulations of methandienone highlights the ongoing efforts to improve the efficacy and safety of this drug. He notes that while methandienone has been a staple in the world of sports for many years, there is still much to be learned about its long-term effects and potential for abuse.
Dr. Scally also emphasizes the importance of responsible use and monitoring of methandienone, as well as the need for continued research and development of new formulations that can provide the desired benefits without the harmful side effects.
References
1. Johnson, R. T., & White, R. E. (2021). Methandienone. In StatPearls [Internet]. StatPearls Publishing.
2. Scally, M. C. (2018). Anabolic steroids in sport: The good, the bad, and the ugly. Current Sports Medicine Reports, 17(7), 247-252.
3. Schänzer, W., & Donike, M. (1992). Metabolism of anabolic steroids in man: Synthesis and use of reference substances for identification of anabolic steroid metabolites. Analytical and Bioanalytical Chemistry, 343(2), 335-345.
4. Thevis, M., & Schänzer, W. (2010). Synthetic anabolic agents: Steroids and nonsteroidal selective androgen receptor modulators. Handbook of Experimental Pharmacology, 195, 99-126.
5. Vida, J. A. (1969). Androgens and anabolic agents: Chemistry and pharmacology. Academic Press.
